S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The Strategic Gold Play You Haven't Heard About (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The Strategic Gold Play You Haven't Heard About (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
NASDAQ:VRAY

ViewRay (VRAY) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.03
$0.65
52-Week Range
N/A
Volume
108.50 million shs
Average Volume
7.51 million shs
Market Capitalization
$4.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.18

ViewRay MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
∞ Upside
$3.18 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$519,974 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars


VRAY stock logo

About ViewRay (NASDAQ:VRAY) Stock

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.


VRAY Stock News Headlines

ViewRay Inc (6L9.BE)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Why ViewRay Stock Hit A New 52-Week Low Today
Why Is ViewRay (VRAY) Stock Down 69% Today?
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
ViewRay® Files Voluntary Chapter 11 Petitions
ViewRay (NASDAQ: VRAY)
Viewray (VRAY) Receives a Hold from Stifel Nicolaus
B.Riley Financial downgrades Viewray (VRAY) to a Hold
BTIG Remains a Hold on Viewray (VRAY)
ViewRay Announces First Quarter 2023 Results
Jefferies Downgrades Viewray (VRAY)
Jefferies downgrades Viewray (VRAY) to a Hold
See More Headlines
Receive VRAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

VRAY Company Calendar

Last Earnings
2/27/2023
Today
9/22/2023
Next Earnings (Estimated)
10/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRAY
Employees
295
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$3.18
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$1.00
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

Net Income
$-107,330,000.00
Net Margins
-104.30%
Pretax Margin
-104.30%

Debt

Sales & Book Value

Annual Sales
$105.86 million
Book Value
$0.45 per share

Miscellaneous

Free Float
178,817,000
Market Cap
$4.59 million
Optionable
Optionable
Beta
0.81

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Scott William DrakeMr. Scott William Drake (Age 55)
    Pres, CEO & Director
    Comp: $1.8M
  • Mr. Robert S. McCormack J.D. (Age 56)
    Chief Legal Officer
    Comp: $692.36k
  • Dr. James F. Dempsey Ph.D. (Age 52)
    Founder & Chief Scientific Officer
  • Mr. William P. Burke (Age 54)
    Exec. VP & CFO
  • Drew Hill
    Sr. VP of Operations & Devel.
  • Matt Harrison
    Director of Investor Relations
  • Karen Hackstaff
    VP of Marketing
  • Mr. Robert Michael Fuchs (Age 56)
    Chief HR Officer
  • Dr. Martin Fuss M.D.
    Ph.D., Chief Medical Officer
  • Mr. Paul Ziegler Jr. (Age 49)
    J.D., Exec. VP & Chief Commercial Officer













VRAY Stock - Frequently Asked Questions

Should I buy or sell ViewRay stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VRAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRAY, but not buy additional shares or sell existing shares.
View VRAY analyst ratings
or view top-rated stocks.

What is ViewRay's stock price forecast for 2023?

7 Wall Street analysts have issued 1 year price targets for ViewRay's stock. Their VRAY share price forecasts range from $1.00 to $8.00. On average, they anticipate the company's share price to reach $3.18 in the next twelve months.
View analysts price targets for VRAY
or view top-rated stocks among Wall Street analysts.

When is ViewRay's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, October 30th 2023.
View our VRAY earnings forecast
.

How were ViewRay's earnings last quarter?

ViewRay, Inc. (NASDAQ:VRAY) posted its earnings results on Monday, February, 27th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The company earned $34.70 million during the quarter, compared to the consensus estimate of $34.65 million. ViewRay had a negative net margin of 104.30% and a negative trailing twelve-month return on equity of 120.48%. The firm's quarterly revenue was up 70.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.16) EPS.

What is Scott Drake's approval rating as ViewRay's CEO?

5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ViewRay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).

When did ViewRay IPO?

(VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

What is ViewRay's stock symbol?

ViewRay trades on the NASDAQ under the ticker symbol "VRAY."

Who are ViewRay's major shareholders?

ViewRay's stock is owned by many different retail and institutional investors. Top institutional investors include Hodges Capital Management Inc. (1.42%), Parallax Volatility Advisers L.P. (0.00%), Royce & Associates LP (0.53%), Jefferies Financial Group Inc. (0.00%), Simplex Trading LLC (0.00%) and Allspring Global Investments Holdings LLC (0.05%). Insiders that own company stock include Adam Andrew Podbelski, B Kristine Johnson, Brian K Roberts, Caley Castelein, Farhad Fred Ebrahimi, Influence Ltd Strong, International Ltd Fosun, James F Dempsey, Karen Prange, Paul Ziegler Jr, Sanket Shah, Scott William Drake, Susan C Schnabel and Zachary William Stassen.
View institutional ownership trends
.

How much money does ViewRay make?

ViewRay (NASDAQ:VRAY) has a market capitalization of $0.00 and generates $105.86 million in revenue each year. The company earns $-107,330,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

How many employees does ViewRay have?

The company employs 295 workers across the globe.

Does ViewRay have any subsidiaries?
The following companies are subsidiares of ViewRay: Vesuvius Acquisition Corp., ViewRay GmbH, and ViewRay Technologies Inc..
Read More
How can I contact ViewRay?

ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The official website for the company is www.viewray.com. The company can be reached via phone at (440) 703-3210, via email at investors@viewray.com, or via fax at 800-417-3459.

This page (NASDAQ:VRAY) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -